These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3801862)

  • 1. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF; Blaha CD; Phillips AG
    Brain Res; 1986 Nov; 397(1):200-4. PubMed ID: 3801862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat.
    Blaha CD; Phillips AG; Lane RF
    Regul Pept; 1987 Jun; 17(6):301-10. PubMed ID: 3602473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin-induced inhibition of dopamine neurotransmission: comparison with chronic haloperidol treatment.
    Lane RF; Blaha CD; Phillips AG
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):291-9. PubMed ID: 2819952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ; Wang RY
    Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F; Ettenberg A; Koob GF
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM; Wang RY; Westfall TC
    J Neurosci; 1985 Oct; 5(10):2744-9. PubMed ID: 4045551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN; Hommer DW; Skirboll LR
    Brain Res; 1985 Jun; 335(2):337-41. PubMed ID: 4005562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study.
    Gerhardt GA; Friedemann M; Brodie MS; Vickroy TW; Gratton AP; Hoffer BJ; Rose GM
    Brain Res; 1989 Oct; 499(1):157-63. PubMed ID: 2804664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin.
    Voigt MM; Wang RY
    Brain Res; 1984 Mar; 296(1):189-93. PubMed ID: 6324955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW; Bianchi BR
    Neuropeptides; 1989 Jan; 13(1):43-50. PubMed ID: 2466220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.
    Marshall FH; Barnes S; Pinnock RD; Hughes J
    Br J Pharmacol; 1990 Apr; 99(4):845-8. PubMed ID: 2361176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: depolarization block as a possible mechanism of action.
    Lane RF; Blaha CD
    Brain Res Bull; 1987 Jan; 18(1):135-8. PubMed ID: 3828839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems.
    Király I; Van Ree JM
    Neurosci Lett; 1987 Mar; 74(3):343-7. PubMed ID: 3561887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry.
    Reum T; Fink H; Marsden CA; Morgenstern R
    Neuropeptides; 1998 Apr; 32(2):161-6. PubMed ID: 9639255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute thioridazine stimulates mesolimbic but not nigrostriatal dopamine release: demonstration by in vivo electrochemistry.
    Lane RF; Blaha CD
    Brain Res; 1987 Apr; 408(1-2):317-20. PubMed ID: 2439169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.
    Daugé V; Steimes P; Derrien M; Beau N; Roques BP; Féger J
    Pharmacol Biochem Behav; 1989 Sep; 34(1):157-63. PubMed ID: 2626446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward.
    Vaccarino FJ; Koob GF
    Neurosci Lett; 1984 Nov; 52(1-2):61-6. PubMed ID: 6098878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G; Gaudreau P; Quirion R; de Montigny C
    J Neurosci; 1990 Feb; 10(2):469-78. PubMed ID: 2137531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.